tradingview.com
Cure8 news brief
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - TradingView
Medications
Risankizumab
Upadacitinib
Adalimumab
IL-23 inhibitor
JAK inhibitor
Anti-TNF
Market or Business News
Why This Matters
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in IBD.
Changes in approvals, new formulations, or successful phase III programs could affect future access and prescribing.
Who Should Pay Attention
Adult patients with IBD (Crohn’s disease or ulcerative colitis), people on biologics or JAK inhibitors, clinicians who prescribe these drugs, and researchers or investors tracking immunology drug development.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
AbbVie’s immunology franchise — led by Skyrizi (risankizumab) and Rinvoq (upadacitinib) — is the focus of this business/market piece. The article summarizes recent sales performance, regulatory and indication expansion efforts (including IBD indications), and AbbVie’s pipeline and BD activity (acquisitions and combination programs aimed at IBD).
It notes EU approvals for additional Rinvoq indications and ongoing FDA reviews, phase III programs, and Skyrizi-based combination candidates (ABBV-382, ABBV-701) targeting IBD. The piece is a financial/industry analysis rather than clinical guidance.
It highlights expected revenue trajectories, competitive threats from other pharma companies, and AbbVie’s strategy to extend growth via internal R&D and acquisitions. It does not provide clinical trial results or patient-level data.
If you are following IBD treatments, the relevant takeaways are the emphasis on Skyrizi and Rinvoq growing in IBD, ongoing clinical development of combination regimens and subcutaneous induction strategies, and AbbVie’s pursuit of new indications and assets that could affect future treatment options and market availability.
Keep In Mind
This is a finance/industry article focused on company performance, pipeline strategy, and market forecasts—not a clinical study report. It references regulatory filings and upcoming phase III readouts but does not present new clinical efficacy or safety data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 10, 2026, 5:52 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance? - TradingView
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.